ProMIS Neurosciences Inc

NASDAQ:PMNUnited States

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Contact Information

Headquarters

Suite 200, 1920 Yonge StreetTORONTO, ON, Canada M4S 3E2

Phone

416-847-6898

Fax

---

Executives

Executive Chairman of the Board

Eugene Williams

Interim Chief Executive Officer, Director

Neil Warma

Co-Founder, Chief Scientific Officer, Director

Neil Cashman

Chief Financial Officer

Daniel Geffken

Chief Operating Officer

Gavin Malenfant